Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/jfprhc-2012-100428 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
"Trust Women": Characteristics of and learnings from patients of a Shield Law medication abortion practice in the United States.
Perspect Sex Reprod Health
September 2024
Cambridge Reproductive Health Consultants, Cambridge, Massachusetts, USA.
Introduction: The 2022 Massachusetts Shield Law protects telemedicine providers who care for abortion seekers in other states from criminal, civil, and licensure penalties. In this article we explore the characteristics of patients of The Massachusetts Medication Abortion Access Project (The MAP).
Methods: The MAP is an asynchronous telemedicine service that offers mifepristone/misoprostol to abortion seekers in all 50 states who are at or under 11 weeks pregnancy gestation on initial intake.
Society of Family Planning Clinical Recommendation: Medication abortion between 14 0/7 and 27 6/7 weeks of gestation: Jointly developed with the Society for Maternal-Fetal Medicine.
Am J Obstet Gynecol
October 2023
Department of Obstetrics & Gynecology, Division of Maternal-Fetal Medicine, Massachusetts General Hospital, Obstetrics and Gynecology, Yawkey Center for Outpatient Care, Boston, MA, United States.
The objective of this Clinical Recommendation is to review relevant literature and provide evidence-based recommendations for medication abortion between 14 0/7 and 27 6/7 weeks of gestation, with a focus on mifepristone-misoprostol and misoprostol-only regimens. We systematically reviewed PubMed articles published between 2008 and 2022 and reviewed reference lists of included articles to identify additional publications. See Search Strategy for more details.
View Article and Find Full Text PDFSociety of Family Planning Clinical Recommendation: Medication abortion between 14 0/7 and 27 6/7 weeks of gestation: Jointly developed with the Society for Maternal-Fetal Medicine.
Contraception
September 2023
Department of Obstetrics & Gynecology, Division of Maternal-Fetal Medicine, Massachusetts General Hospital, Obstetrics and Gynecology, Yawkey Center for Outpatient Care, Boston, MA, United States.
The objective of this Clinical Recommendation is to review relevant literature and provide evidence-based recommendations for medication abortion between 14 0/7 and 27 6/7 weeks of gestation, with a focus on mifepristone-misoprostol and misoprostol-only regimens. We systematically reviewed PubMed articles published between 2008 and 2022 and reviewed reference lists of included articles to identify additional publications. See Search Strategy for more details.
View Article and Find Full Text PDFSociety of Family Planning Clinical Recommendation: Medication abortion between 14 0/7 and 27 6/7 weeks of gestation.
Contraception
September 2023
Massachusetts General Hospital, Obstetrics and Gynecology, 55 Fruit St., Yawkey Center for Outpatient Care, Suite 4F, Boston, MA 02114. Electronic address:
Objective: The objective of this Clinical Recommendation is to review relevant literature and provide evidence-based recommendations for medication abortion between 14 0/7-27 6/7 weeks of gestation, with focus on mifepristone-misoprostol and misoprostol-only regimens.
Methods: We systematically reviewed PubMed articles published between 2008 and 2022 and reviewed reference lists of included articles to identify additional publications. See Search Strategy for more details.
Improving access to medicines for early medical abortion: learning from experiences of medicines licensing and service delivery.
BMJ Sex Reprod Health
October 2023
Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!